Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Built Environments And Child Health in WalEs and AuStralia (BEACHES): a study protocol.
Pedrick-Case R, Bailey R, Beck B, Beesley B, Boruff B, Brophy S, Cross D, Dhamrait G, Duncan J, Gething P, Johnson RD, Lyons RA, Mizen A, Murray K, Pouliou T, Rafferty J, Robinson T, Rosenberg M, Schipperijn J, Thompson DA, Trost SG, Watkins A, Stratton G, Fry R, Christian H, Griffiths LJ. Pedrick-Case R, et al. Among authors: beesley b. BMJ Open. 2022 Oct 25;12(10):e061978. doi: 10.1136/bmjopen-2022-061978. BMJ Open. 2022. PMID: 36283749 Free PMC article.
Understanding variations in the built environment over time to inform longitudinal studies of young children's physical activity behaviour - The BEACHES project.
Robinson T, Boruff B, Duncan J, Murray K, Schipperijn J, Nathan A, Beck B, Stratton G, Griffiths LJ, Fry R, Beesley B, Christian H. Robinson T, et al. Among authors: beesley b. Health Place. 2024 Nov;90:103345. doi: 10.1016/j.healthplace.2024.103345. Epub 2024 Sep 9. Health Place. 2024. PMID: 39255604 Free article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.